Magna International: BMO Lowers Estimates On Lower Production Expectations

On August 16 BMO Capital Markets slightly lowered their 12-month price target on Magna International (TSX: MG) while reiterating their outperform rating. They say the reason for the price target change is due to revising their third quarter earnings per share estimate to $1.47 from $1.63.

Magna International has 10 analysts covering the stock, with 1 having a strong buy rating, 8 have buy ratings and 1 analyst has a hold rating. The consensus 12-month price target sits at $111 while the street high comes in at $129.45 and the lowest is $88.

With the chip shortage still heavily in effect, BMO has lowered its expectations around production. They say that the West Detroit Three production is now expected to increase 31% sequentially, lower than their original 50% estimate. The companies revenue meanwhile is expected to grow 14%, underperforming its production increase.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

The company’s western production is expected to decrease 4.5% sequentially, which is 1% weaker than their original estimate. Revenues from Magna’s European platforms are estimated to decrease 5.5% sequentially. This is primarily due to the companies top platforms, the BMW 1-Series and Volkswagen Tiguan, both expected to drop 22% sequentially.

Below you can see BMO’s updated third quarter, full year 2021, and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Three Million Ounces of Gold, Barely Getting Started | Dylan Langille – White Gold

Building the $500M-a-Year Gold Mine | Victor Cantore – Amex Gold Mining

Building the Next 500,000-Ounce Gold Producer | Stephen Soock – Heliostar Metals

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Curaleaf: Cormark Upgrades To Buy Rating, Canaccord, Haywood Raise Price Targets

After Curaleaf’s (CSE: CURA) record-breaking second-quarter numbers, analysts have upgraded their twelve-month price targets. Curaleaf...

Wednesday, August 19, 2020, 11:29:55 AM

Medmen: Cantor Reiterates Ratings After Call With Management

On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth quarter financial results. The...

Friday, October 8, 2021, 03:42:00 PM

Canaccord Raises Coinbase Price Target Following Strong Earnings Growth

On August 10, Coinbase Global (NASDAQ: COIN) reported its second-quarter financial statements. For non-GAAP items,...

Saturday, August 14, 2021, 04:04:00 PM

NG Energy: Beacon Reiterates Buy Rating, Suggests Firm Could Move Beyond $2.80 Price Target

On January 4th, NG Energy (TSXV: GASX) announced that it has completed all civil works and...

Sunday, January 9, 2022, 11:17:00 AM

Stifel-GMP: Canopy Growth CEO’s Legacy is “Poor Execution, Misallocated Capital, and Mismanaged Expectations.”

Earlier this month, Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) reported their fiscal second-quarter 2022...

Sunday, November 21, 2021, 12:03:00 PM